PMM

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

A Momentous 2023, Headlined by a 19% increase of ARR, Positions Percona for Even Greater Success in the Year Ahead

Retrieved on: 
Wednesday, March 27, 2024
Data Management, Security, Apps, Applications, Technology, Software, Internet, Automation, Database, PagerDuty, CLI, Percona Server for MySQL, Netflix, ARR, Geological survey, EveryMatrix, PostgreSQL, Publication, DevOps, InfoWorld, MongoDB, Computer Weekly, PMM, MySQL, Gartner, Information management, CVE, UI, MariaDB

The company's impressive 2023 has further solidified its standing as a go-to provider of open source database solutions and support services.

Key Points: 
  • The company's impressive 2023 has further solidified its standing as a go-to provider of open source database solutions and support services.
  • Uniquely qualified to address these needs, Percona has capitalized on the expanding opportunity, realizing a 19% increase in Annual Recurring Revenue (ARR).
  • Percona Everest allows users to enjoy flexible features such as provisioning, scalability, performance optimization, and high availability with full automation.
  • At these events, and many others, Percona will continue to expand its impact on the open source database community.

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Retrieved on: 
Tuesday, March 19, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Precision BioSciences, Conference, Gene editing, Cell, CTA, Mitochondrial myopathy, Mitochondrion, DNA, Smith, Doctor of Philosophy, IND, CRISPR, Heteroplasmy, PMM, Vaccine

These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March 18-20, 2024 in Hinxton, UK.

Key Points: 
  • These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March 18-20, 2024 in Hinxton, UK.
  • “Today’s data from our PBGENE-PMM program further validate our work with ARCUS and continue to demonstrate its ability to make precise edits while avoiding off-target activity,” said Jeff Smith, PhD, Chief Research Officer of Precision BioSciences.
  • PBGENE-PMM is designed to eliminate mutant mitochondrial DNA leaving normal functioning wild-type mitochondrial DNA intact to repopulate the cell, resulting in a shift in heteroplasmy and improvement in mitochondrial function.”
    Smith continued, “Additionally, ARCUS can cross mitochondrial membranes in order to access the mitochondrial DNA.
  • Together, these data support the development of PBGENE-PMM as a single-treatment, in vivo gene editing therapeutic for m.3243-associated primary mitochondrial myopathy.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, January 9, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Therapy, PMM, ATM, Precision, Precision BioSciences, VWAP, Imugene, Cancer, Economics, Optimism, Multiple myeloma, HBV, Immunology, Gene editing, BCMA, Vaccine

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points: 
  • “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
  • Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
  • Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
  • These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

Automotive Transmission Dynamometer Market size in North America to grow by USD 565.05 million from 2023 to 2028; Future Scope and Innovations

Retrieved on: 
Thursday, January 11, 2024
College of Engineering (KNUST), Load testing, Challenge, Growth, Reciprocating engine, Automotive engineering, LINK, Gesellschaft mit beschränkter Haftung, Transmission, Originality, Innovation, Investment, Original equipment manufacturer, Development, PMM, Torque, NTS, Calibration, AVL, USD, Cost, Research, Instrumentation

The North America Automotive Transmission Dynamometer Market is driven by increased R&D investments due to cost pressures faced by automotive OEMs, spurred by compliance with environmental and safety standards.

Key Points: 
  • The North America Automotive Transmission Dynamometer Market is driven by increased R&D investments due to cost pressures faced by automotive OEMs, spurred by compliance with environmental and safety standards.
  • The automotive transmission dynamometer market in North America is fragmented owing to the presence of many global and regional companies.
  • Major Challenges - The North America Automotive Transmission Dynamometer Market confronts a notable challenge due to a shortage of skilled personnel adept in dynamometer testing, impacting Transmission Efficiency and Automotive Test Systems.
  • The automotive clutch actuator market size is estimated to grow by USD 7,601.28 million at a CAGR of 11.68% between 2023 and 2028.

Flash News: OKX Welcomes DODO's Integration with X1 Testnet

Retrieved on: 
Wednesday, December 27, 2023
Maker, Ethereum, Knowledge, ZK, OKX, EVM, Polygon, CDK, PMM, Web3, Cryptocurrency

X1 is a highly performant and secure network, leveraging the robust capabilities of the Polygon Chain Development Kit (CDK) .

Key Points: 
  • X1 is a highly performant and secure network, leveraging the robust capabilities of the Polygon Chain Development Kit (CDK) .
  • With this integration, DODO users can access a wider range of liquidity pools and trading opportunities within the X1 ecosystem.
  • The integration of DODO with X1 provides users and developers with the opportunity to explore the capabilities of OKX's Layer 2 network in a controlled environment.
  • Since its launch in November 2023, the X1 testnet has attracted over 50 projects, including QuickSwap and Galxe, fostering innovation and collaboration within the Web3 community.

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Retrieved on: 
Thursday, December 14, 2023
Investment, Patient, Science, PMM, STRIDE, Pharmaceutical industry

IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study (NCT04535609) of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoint. The primary efficacy endpoint of the trial was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24. The secondary efficacy endpoint was the change from baseline in the PROMIS® Short Form Fatigue 13a score.

Key Points: 
  • IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study ( NCT04535609 ) of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoint.
  • The primary efficacy endpoint of the trial was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24.
  • The secondary efficacy endpoint was the change from baseline in the PROMIS® Short Form Fatigue 13a score.
  • “We are immensely thankful to all the patients, families, and healthcare professionals who participated in the mavodelpar PMM development program,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
STRIDE, Three Months, DNA, Therapy, Treatment, PMM, Investment, PPAR, Patient, Research, G&A, R, Patent, A-DNA, Pharmaceutical industry, Nursing, Disease

IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • “We are looking forward to sharing topline results of our pivotal STRIDE study in December,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • Research and development (R&D) expenses were $13.6 million during the third quarter of 2023, compared to $9.9 million for the same period in 2022.
  • General and administrative (G&A) expenses were $7.3 million during the third quarter of 2023, compared to $3.9 million for the same period in 2022.

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Retrieved on: 
Monday, December 4, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, General Health, Science, Oncology, Mitochondrial disease, Anatomy, Cell biology, DNA, Gene editing, PMM, IND, Liver, Patient, University, CRISPR, Mitochondrial myopathy, Doctor of Philosophy, CTA, A-DNA, Manuscript, MELAS, Mutation, Cell, Nature Metabolism, Precision BioSciences, Vaccine, Neurology

For mitochondrial diseases, what makes ARCUS such an elegant and simple tool is that it is a single protein that both recognizes and eliminates the mutant mitochondrial DNA,” said Jeff Smith, Ph.D., Chief Research Officer of Precision BioSciences.

Key Points: 
  • For mitochondrial diseases, what makes ARCUS such an elegant and simple tool is that it is a single protein that both recognizes and eliminates the mutant mitochondrial DNA,” said Jeff Smith, Ph.D., Chief Research Officer of Precision BioSciences.
  • “Today’s publication further validates the ability of ARCUS to overcome the limitations of CRISPR-based gene editing technologies for treating mitochondrial disease and eliminating mutated mitochondrial DNA with high specificity to improve overall mitochondrial function.
  • By eliminating the mutant mitochondrial DNA and allowing the wild-type mitochondrial DNA to repopulate, mitoARCUS drives a shift toward healthy mitochondrial DNA, a process known as shifting heteroplasmy.
  • “To date, there are no curative treatments for mitochondrial diseases, so a gene editing approach is a novel way to offer hope to the patients suffering from mitochondrial myopathy.

ZINFI Releases Complimentary Guidebook Providing an Overview of Best Practices in Partner Relationship Management

Retrieved on: 
Tuesday, November 7, 2023
Ebook, AMM, Feedback, Guide, UPM, PMM, Organization, Building Bridges, PIM, Marketing, Chapter One, PRM, Automation, Online shopping, G2

PLEASANTON, Calif., Nov. 7, 2023 /PRNewswire/ -- ZINFI Technologies, Inc., a company leading the definition and creation of Unified Partner Management (UPM) solutions, today announced that its latest guidebook — Building Bridges: Best Practices in Partner Relationship Management — is now available as a complimentary downloadable eBook. ZINFI's latest guidebook provides a broad overview of partner relationship management (PRM) with a focus on best practices that lead to more robust and fruitful relationships with partners, more efficient partner programs and more profitable results.

Key Points: 
  • ZINFI's latest guidebook provides a broad overview of partner relationship management (PRM) with a focus on best practices that lead to more robust and fruitful relationships with partners, more efficient partner programs and more profitable results.
  • Building Bridges: Best Practices in Partner Relationship Management is divided into two parts.
  • It also presents overviews of the specific modules available for affiliate marketing management (AMM), partner relationship management (PRM), partner marketing management (PMM) and partner incentives management (PIM).
  • To access more information about ZINFI's partner relationship management platform or to download a copy of ZINFI's best practices guide on partner relationship management , please visit our website at www.zinfi.com.